Antibacterial medicine sales in Australia for 2024 are projected to be 284.9 million US Dollars PPP, increasing steadily year-on-year to reach 304.0 million US Dollars PPP by 2028. This reflects an average annual growth rate (CAGR) of around 1.65% over the forecast period.
The year-on-year growth rates are as follows:
- 2024: Baseline
- 2025: +1.69%
- 2026: +1.66%
- 2027: +1.63%
- 2028: +1.57%
In 2023, the actual sales value stood at 280.2 million US Dollars PPP. The previous two years have seen a modest increase, maintaining a positive growth trajectory into the forecast period.
Future trends to watch for include the impact of new antimicrobial resistance strategies, potential regulatory changes, and market dynamics driven by emerging pathogens. Continued advancements in medical research and health policy adaptations could significantly influence antibacterial medicine sales.
